Literature DB >> 26861724

MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK).

Ying Huang, Yang Yang, Yong He, Cheng Huang, Xiaoming Meng, Jun Li1.   

Abstract

INTRODUCTION: MicroRNA-208a (miR-208a) exacerbated cardiomyocyte apoptosis via inhibiting nemo-like kinase (NLK). miR-208a is a crucial molecule in the regulation of heart diseases, however, the biological function and underlying mechanism of miR-208a in the progression of cardiomyocyte apoptosis is not clearly elucidated. We hypothesized that miR-208a might potentiate cardiomyocyte apoptosis through inhibiting NLK.
METHODS: Male Sprague-Dawley rats were underwent permanent coronary artery ligation to establish myocardial infarction (MI) model. The quantitative real-time RT-PCR (qRT-PCR) was used to evaluate the expression of miR-208a and NLK mRNA. Western blot was applied to detect NLK and Bcl-2 proteins expression. Luciferase reporter assay was performed to indentify NLK as a target of miR-208a. The apoptosis of H9C2 cells was assessed by flow cytometry (FCM).
RESULTS: miR-208a was upregulated accompanying with a significant decrease of NLK in response to MI, and stronger miR-208a staining was detected by in situ hybridization in the cytoplasm of cardiomyocytes in MI group compared to the sham group. In vitro, overexpression of miR-208a greatly enhance Ang II-induced the apoptosis of H9C2 cells through downregulating of NLK and the anti-apoptosis protein Bcl-2 expression, whereas these effects were reversed when miR-208a was downregulated. Dual luciferase reporter assay and western blot results demonstrated that NLK was a direct target of miR-208a. Interestingly, upregulation of NLK obviously increased Bcl-2 expression and reduced the percentage of apoptotic cells, while attenuation of NLK reduced the level of Bcl-2 and cells apoptosis after treatment with Ang II.
CONCLUSIONS: miR-208a can promote Ang II-induced cardiomyocyte apoptosis via negatively regulating NLK expression, and inhibition of miR-208a may provide a novel therapeutic target for cardiomyocyte apoptosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26861724     DOI: 10.2174/1381612822666160210143047

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Extracellular vesicles-mediated transfer of miR-208a/b exaggerate hypoxia/reoxygenation injury in cardiomyocytes by reducing QKI expression.

Authors:  Feng Wang; Yuxiang Yuan; Pirong Yang; Xia Li
Journal:  Mol Cell Biochem       Date:  2017-03-10       Impact factor: 3.396

Review 2.  Non-coding RNAs as biomarkers for acute myocardial infarction.

Authors:  Chen Wang; Qing Jing
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

Review 3.  The Impact of microRNAs in Renin-Angiotensin-System-Induced Cardiac Remodelling.

Authors:  Michaela Adamcova; Ippei Kawano; Fedor Simko
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

4.  Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.

Authors:  Yuan Chen; Lei Fang; Jiali Zhang; Gefei Li; Mengni Ma; Changxi Li; Jianxin Lyu; Qing H Meng
Journal:  Int J Mol Sci       Date:  2017-03-09       Impact factor: 5.923

5.  A systematic integrative approach reveals novel microRNAs in diabetic nephropathy.

Authors:  Farnoush Kiyanpour; Maryam Abedi; Yousof Gheisari
Journal:  J Res Med Sci       Date:  2020-01-20       Impact factor: 1.852

6.  miRNA-Coordinated Schizophrenia Risk Network Cross-Talk With Cardiovascular Repair and Opposed Gliomagenesis.

Authors:  Hongbao Cao; Ancha Baranova; Weihua Yue; Hao Yu; Zufu Zhu; Fuquan Zhang; Dongbai Liu
Journal:  Front Genet       Date:  2020-03-04       Impact factor: 4.599

7.  Overexpression of miR-375 Protects Cardiomyocyte Injury following Hypoxic-Reoxygenation Injury.

Authors:  Md Sayed Ali Sheikh
Journal:  Oxid Med Cell Longev       Date:  2020-01-03       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.